COMMUNIQUÉS West-GlobeNewswire

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
06/08/2025
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA [...]
HilleVax Reports Second Quarter 2025 Financial Results
06/08/2025
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the [...]
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
06/08/2025
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker [...]
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
06/08/2025
ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance
06/08/2025
Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic. The Board thanks Lou Panaccio, its long-standing Board Chair, for his [...]
Cytek Biosciences Reports Second Quarter 2025 Financial Results
06/08/2025
FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second [...]
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
06/08/2025
Following Interactions with FDA on VAX-31 Adult Program, Including End-of-Phase 2 Meeting, Company Finalizing Phase 3 Clinical Program to Validate VAX-31 as Potential New Standard-of-Care Adult PCV ; Pivotal, Non- [...]
Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
06/08/2025
– Third quarter fiscal 2025 revenue up 23.5% to $130.7 million – Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million – Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 06, 2025 [...]
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
06/08/2025
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
06/08/2025
Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy [...]
ONWARD Medical annonce la nomination de Lucas Buchanan à son conseil d’administration
06/08/2025
M. Buchanan est l’ancien directeur financier et directeur des opérations de Silk Road Medical, où il a développé avec succès une entreprise de dispositifs médicaux en phase de croissance, aboutissant à son acquisition [...]
Immix Biopharma Announces Other Serious Diseases Strategy
06/08/2025
– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – – On track for first Biologics License Application (BLA) approved cell therapy [...]
NADP Foundation Issues Request for Proposals
06/08/2025
DALLAS, Aug. 06, 2025 (GLOBE NEWSWIRE) -- To solicit projects advancing access to oral health care, the National Association of Dental Plans (NADP) Foundation issued its 2025 request for proposal (RFP) on Aug. 1. The [...]
Brain Injury Association of America to Honor Centre for Neuro Skills’ Dr. Mark Ashley as Luminary of the Year
06/08/2025
BAKERSFIELD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Brain Injury Association of America (BIAA) will honor Dr. Mark J. Ashley, Founder and Executive Chairman of the Board of Centre for Neuro Skills (CNS), as [...]
Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy
06/08/2025
CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, announced today that it has entered into a [...]
Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
06/08/2025
ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, [...]
PacBio to Present at Upcoming Investor Conferences
06/08/2025
MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the [...]
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)
06/08/2025
There will be presentations on the latest positive progress from AIM’s clinical program in pancreatic cancer, the positive therapeutic effects of AIM’s drug Ampligen on multiple cancer types, and Ampligen’s mechanism of [...]
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
06/08/2025
– Company to Host Conference Call on August 13, 2025, at 4:30 p.m. ET – SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and [...]

Pages